RxDoctor Payments Data

Cortney Barrett, NP

Family · Watonga, OKNPI 1265151757

Payments from drug & device makers

$439in general payments, 2019–2025

Across 15 payments — averaging $29.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$169
  • AbbVie$50
  • Dexcom, Inc.$49
  • Novo Nordisk$45
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$40
  • Lilly USA, LLC$36
  • plus $50 from 3 others

What the payments were for

  • Food & beverage$439100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$439 in reported general payments places this provider in the 50th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$67,002
Medicare patients
154
Services billed
1,829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin55$40,040
MounjaroTirzepatide25$26,945
EliquisApixaban37$26,584
TrulicityDulaglutide21$20,425
OzempicSemaglutide21$19,707
Spiriva RespimatTiotropium Bromide14$12,111
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,763
LinzessLinaclotide16$8,804
Breo ElliptaFluticasone/Vilanterol21$8,574
FarxigaDapagliflozin Propanediol15$8,573
Tresiba Flextouch U-200Insulin Degludec13$8,375
MovantikNaloxegol Oxalate12$5,059
Incruse ElliptaUmeclidinium Bromide12$4,079
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$3,603
Albuterol Sulfate HfaAlbuterol Sulfate96$2,489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$19$52,15069 claims
Lilly USA, LLCMounjaro, Trulicity$36$47,37046 claims
Novo NordiskOzempic$45$19,70721 claims
AbbVieLinzess$50$8,80416 claims
AstraZenecaFarxiga$16$8,57315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,026 family providers in Oklahoma.

Other family in Watonga

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →